Fortress Biotech, Inc.

  • Home
  • About
    • Overview
    • Business Development
    • Management Team
    • Board of Directors
    • FAQ
  • Programs
    • Pipeline
    • Marketed Products
    • Publications
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Resources
  • Contact
  • Careers
  • Accessibility Statement

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Mustang Bio Announces $12.8 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-101 in Malignant Glioma

Oct 11, 2017

Checkpoint Therapeutics Initiates Phase 1 Study of Anti-PD-L1 Antibody CK-301

Oct 05, 2017

Avenue Therapeutics Announces Dosing of First Patient in Pivotal Phase 3 Clinical Trial of Intravenous Tramadol for the Management of Postoperative Pain

Sep 27, 2017

Checkpoint Therapeutics to Present at the Ladenburg Thalmann 2017 Healthcare Conference

Sep 20, 2017

Mustang Bio Announces Expansion of CAR T Pipeline into CD20-Directed Immunotherapies

Sep 14, 2017

Checkpoint Therapeutics Receives Orphan Drug Designation for CK-101 for the Treatment of EGFR Mutation-Positive Non-Small Cell Lung Cancer

Sep 11, 2017

Checkpoint Therapeutics to Present at the 19th Annual Rodman & Renshaw Global Investment Conference

Sep 05, 2017

Fortress Biotech to Present at the 19th Annual Rodman & Renshaw Global Investment Conference

Sep 05, 2017

Mustang Bio to Present at the CAR-TCR Summit 2017

Sep 05, 2017

Mustang Bio Commences Trading on the NASDAQ Global Market

Aug 22, 2017
RSS
  • Prev
    • 1...
    • 35
    • 36
    • 37
    • 38
    • 39
    • 40
    • 41
    • 42
    • 43
    • 44
    • ...46
    Next

    Fortress Biotech programs include product candidates in development at Fortress, its majority-owned and majority-controlled partner companies and entities in which it holds minority ownership positions.

    © 2022 Fortress Biotech, Inc. All Rights Reserved.
    Facebook Twitter Linkedin
    Accessibility Statement Privacy Policy Disclaimer Sitemap